Brief: Immix Biopharma Receives Review Board Approval To Enroll Pediatric Patients In Upcoming Imx-110 Clinical Trial
11/11/2022 13:18
Nov 11 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIX BIOPHARMA RECEIVES INSTITUTIONAL REVIEW BOARD
APPROVAL TO
ENROLL PEDIATRIC PATIENTS IN UPCOMING IMX-110 CLINICAL TRIAL,
KEY REQUIREMENT FOR U.S. FOOD AND DRUG ADMINISTRATION APPROVAL
OF RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER
Source text for Eikon: ID:nGNXcbpymD
Further company coverage: IMMX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary